The ability of cancer cells to migrate is strongly correlated with malignant progression and metastasis. Survival signals that suppress apoptosis have also been linked to increased cell motility. We previously reported that suppression of protein kinase Cd (PKCd) provided survival signals in a rat fibroblast model system. These studies have been extended to human breast cancer cells with differential cell motilities and PKCd levels. BT-549 cells, which lack detectable expression of PKCd, migrate very efficiently, whereas MCF-7 cells, which express high levels of PKCd, migrate very poorly. Ectopic expression of PKCd suppressed cell migration in the BT-549 cells, and downregulation of PKCd enhanced cell migration in the MCF-7 cells. Downregulation of PKCd in the MCF-7 cells also led to increased secretion of the matrix metalloprotease MMP-9. The migration of mouse embryo fibroblasts (MEFs) from wild type and PKCd knockout mice was also examined and MEFs from PKCd knockout mice had a five-fold increase in cell migration relative to the wild-type MEFs. These data provide evidence that PKCd suppresses cell migration in both human breast cancer cells and in primary mouse fibroblasts, and indicate that the loss of PKCd in human cancers could contribute to both cell survival and metastasis.
The ability of cancer cells to migrate is strongly correlated with malignant progression and metastasis. Survival signals that suppress apoptosis have also been linked to increased cell motility. We previously reported that suppression of protein kinase Cd (PKCd) provided survival signals in a rat fibroblast model system. These studies have been extended to human breast cancer cells with differential cell motilities and PKCd levels. BT-549 cells, which lack detectable expression of PKCd, migrate very efficiently, whereas MCF-7 cells, which express high levels of PKCd, migrate very poorly. Ectopic expression of PKCd suppressed cell migration in the BT-549 cells, and downregulation of PKCd enhanced cell migration in the MCF-7 cells. Downregulation of PKCd in the MCF-7 cells also led to increased secretion of the matrix metalloprotease MMP-9. The migration of mouse embryo fibroblasts (MEFs) from wild type and PKCd knockout mice was also examined and MEFs from PKCd knockout mice had a five-fold increase in cell migration relative to the wild-type MEFs. These data provide evidence that PKCd suppresses cell migration in both human breast cancer cells and in primary mouse fibroblasts, and indicate that the loss of PKCd in human cancers could contribute to both cell survival and metastasis. Oncogene (2005) Jackson and Foster, 2004 , for a review). Upon treatment with tumorpromoting phorbol esters, PKC isoforms become membrane associated and activated. However, prolonged phorbol ester treatment leads to proteolytic degradation of PKC isoforms via the ubiquitin/proteasome pathway (Lu et al., 1998) . We demonstrated previously that 3Y1 rat fibroblasts overexpressing a tyrosine kinase become transformed when PKCd is downregulated (Lu et al., 1997 (Lu et al., , 1998 Hornia et al., 1999; Zhong et al., 2001) . These studies indicated that the tumor-promoting effects of phorbol esters are due to the downregulation of a tumor suppressing effect of PKCd. This conclusion was supported by subsequent studies in mice engineered to express elevated PKCd in their skin. Such mice were resistant to the tumor promoting effects of phorbol esters (Reddig et al., 1999) . Other studies have also suggested negative effects for PKCd on cell proliferation (Mischak et al., 1993; Acs et al., 1997) , and studies of PKCd knockout mice recently demonstrated negative regulation of B-cell proliferation by PKCd (Miyamoto et al., 2002) . PKCd was recently reported to respond to DNA damage by activating the stress-activated protein kinase (SAPK/ JNK) signaling pathway (Yoshida et al., 2002) , which negatively regulates cell proliferation. PKCd was also reported to be required for DNA-damaged induced increases in p53 expression (Abbas et al., 2004) . Collectively, these data are consistent with PKCd having a tumor suppressing effect that involves the suppression of cell proliferation. Downregulation of PKCd also prevented apoptosis in cells deprived of growth factors (Zhong et al., 2002) , indicating that downregulating PKCd can lead to the generation of survival signals. Interestingly, there is a correlation between survival signaling and cell migration (Di Cristofano and Pandolfi, 2000) . Inhibition of the phosphatidylinositol-3-kinase/Akt survival pathway has been reported to block cell migration (Sliva et al., 2002; Sugatani et al., 2003) . Since downregulating PKCd provides survival signals (Zhong et al., 2002) , it is possible that downregulating PKCd would enhance cell migration. In this report, we describe the effects of PKCd on cell migration in the human breast cancer cells and in mouse embryo fibroblasts (MEFs) from PKCd knockout mice.
PKCd expression correlates with reduced cell motility in MCF-7 and BT-549 breast cancer cells BT-549 breast cancer cells have been reported to have little or no expression of PKCd (Nieves-Neira and Pommier, 1999), whereas MCF-7 cells have been shown to have high levels of PKCd expression (Abbas et al., 2004) . In Figure 1a , the level of PKCd in these two cell lines was compared directly, and as reported previously, there were high levels of PKCd in MCF-7 cells, whereas PKCd expression was undetectable in the BT-549 cells. Having established the differential level of PKCd expression, the ability of the BT-549 cells to migrate in a modified Boyden chamber transwell assay was examined. As shown in Figure 1b , the BT-549 cells were highly mobile relative to the MCF-7 cells, which have previously been reported to be weakly mobile (Johnson et al., 1999; Liu et al., 2002) . There was about a 10-fold difference in the ability of BT-549 cells to cross the Boyden chamber membrane relative to the MCF-7 cells. These data reveal a correlation between PKCd expression and reduced cell motility.
To determine whether the lack of PKCd was important for the migration of the BT-549 cells, these cells were transiently transfected with either a PKCd expression vector (pSRD-PKCd) or an empty vector control and the level of PKCd was verified by Western blot ( Figure 1c ). As shown in Figure 2d , the PKCd expression vector suppressed the ability of the BT-549 cells to migrate by more than 50%. Thus, the lack of PKCd expression in the BT-549 cells is apparently critical for their ability to migrate.
Suppression of PKCd expression in MCF-7 cells enhances cell motility
While MCF-7 cells do not migrate by themselves (Bartucci et al., 2002) , 12-O-tetradecanoyl phorbol-13-acetete (TPA) has been reported to enhance metastatic phenotypes, including cell motility in MCF-7 cells (Johnson et al., 1999; Liu et al., 2002) . We reported previously that tumor-promoting effects of phorbol esters are mediated by the downregulation of PKCd (Lu et al., 1997 (Lu et al., , 1998 Hornia et al., 1999; Zhong et al., 2001 Zhong et al., , 2002 . We therefore examined the effect of TPA on PKCd levels in MCF-7 cells. As shown in Figure 2a , TPA led to the downregulation of PKCd that was (a) Wholecell lysates from MCF-7 and BT-549 cells were prepared, normalized for total protein, and subjected to Western blot analysis as described previously (Lu et al., 1998) using antibodies raised against PKCd and actin (Santa Cruz Biotechnology) as indicated.
(b) Cells were placed in transwell chambers for 24 h at which time cells that had migrated to the lower chamber were counted. (c) BT-549 cells were transiently transfected with either pSRD-PKCd (Hata et al., 1993; Ohno et al., 1994) or an empty vector control and PKCd expression was determined 48 h later as in (a). (d) At 48 h after transfection, cells were placed into modified Boyden chambers and cell motility was determined as in (a). The data presented are representative of experiments repeated two times. The MCF-7 and BT-549 human breast cancer cell lines, obtained from the American Type Culture Collection, were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (HyClone). Transwell migration assays were carried out using BIOCOAT t cell culture inserts with polyethelene terephthalate filters (8 mm pore size) on the bottom (BD Biosciences). Single-cell suspensions in serum-free medium containing 0.5% (w/v) bovine serum albumin were added into the inserts. Cells were added at 15 000 cells/insert. The inserts were set into 24-well plates that held 0.75 ml/well DMEM containing 10% serum as a chemo-attractant and incubated under normal growth conditions for 24 h. Cells that had not penetrated the filters were wiped out with cotton swabs, and cells that had migrated to the lower surface of the filters were fixed in methanol and then stained with a 0.2% (v/v) solution of crystal violet in 2% (v/v) ethanol. Cells that had migrated to the lower surface were counted under a microscope and the mean of five individual fields in the center of the filter where migration was the highest was obtained for each well. Transfections were performed using LipofectAMINE PLUS TM reagent (GIBCO) according to the vendor's instructions. Transfection efficiency was determined by transfection of pEGFP-C1 (Clonetech), which expresses green fluorescent protein. The percentage of green cells was determined microscopically and was routinely in excess of 60% Suppression of cell migration by PKCd D Jackson et al observed most dramatically between 8 and 12 h and was barely detectable by 24 h. Bryostatin1 is a compound that has many properties in common with TPA except that it specifically prevents downregulation of the d isoform of PKC (Hennings et al., 1987; Szallasi et al., 1994a, b) and prevents the tumor-promoting properties of TPA (Hennings et al., 1987; Lu et al., 1997) . Consistent with these reports, bryostain1 prevented downregulation of PKCd by TPA (Figure 2b ). These data reveal that in response to TPA, PKCd is downregulated in MCF-7 cells and that this effect is antagonized by bryostatin1. The ability of TPA to enhance cell migration of the MCF-7 cells was examined in Figure 2c . Consistent with previous reports, the poor motility of MCF-7 cells was substantially increased by TPA. However, the increased motility induced by TPA was blocked by bryostatin1. Bryostatin1 had no effect upon the migration of the BT-549 cells, which have no detectable expression of PKCd (data not shown). These data are consistent with a negative role for PKCd in cell migration and suggest that the ability of TPA to stimulate the migration of MCF-7 cells is due to the downregulation of PKCd.
The secretion of proteases has been correlated with increased migration and metastatic phenotypes (StetlerStevenson and Yu, 2001 ). We therefore examined the effect of TPA and bryostatin on the secretion of the matrix metalloprotease MMP-9. As shown in Figure 2d , TPA also stimulated an increase in MMP-9 secretion that was blocked by bryostatin. These data indicate that downregulation of PKCd also increases the release of a matrix metalloprotease that has been implicated in cell migration and metastasis.
To further establish that the effects of TPA on the migration of MCF-7 cells was due to the downregulation of PKCd, we utilized a catalytically inactive PKCd mutant that acts as a dominant interfering mutant (Hata et al., 1993; Ohno et al., 1994; Lu et al., 1997) . For reasons that are not clear, transient transfection of the dominant-negative PKCd, followed by transfer to the transwell chamber, resulted in poor expression of the PKCd mutant. We therefore performed cell culture wounding assay, where plates were scraped and the ability of cells to migrate into the scraped area was determined. Transient transfection of the kinase dead PKCd into MCF-7 cells led to increased expression of PKCd as shown in Figure 3a , and increased cell motility as measured by migration on plastic (Figure 3b ). The kinase dead PKCd also led to increased MMP-9 release (Figure 3c) . Collectively, the data in Figures 2 and 3 demonstrate that suppression of PKCd in MCF-7 cells increases cell motility and MMP-9 release.
Mouse embryo fibroblasts from PKCd knockout mice have increased cell motility
We next examined the mobility of MEFs from wild type and PKCd knockout mice (Miyamoto et al., 2002) . The lack of PKCd in the MEFs from the PKCd knockout mice was verified by Western blot (Figure 4a) . MEFs, generated from wild type and PKCd knockout mouse embryos, were then added to the modified Boyden chambers and cell motility was examined as in Figure 1 . In Figure 4b it is shown that wild-type MEFs have very little mobility in the transwell assay, whereas MEFs from PKCd knockout mice were highly mobile with more than a five-fold increase in number cells passing through the Boyden chamber membranes. Thus, MEFs lacking PKCd have acquired the ability to migrate. These data further support the hypothesis that PKCd (a) MCF-7 cells were treated with 100 nM TPA for the indicated times. Whole-cell lysates were then prepared, normalized for total protein, and subjected to Western blot analysis using antibodies raised against PKCd and actin as shown. (b) MCF-7 cells were treated with TPA (100 nM) for 24 h where indicated in the presence and absence of 100 nM bryostatin1 (Sigma) as shown. Cell lysates were then subjected to Western blot analysis using antibodies raised against PKCd and actin. (c) The motility of MCF-7 cells was examined in the presence of TPA (100 nM) and/or bryostatin1 (100 nM) as indicated. (d) MMP-9 activity in the conditioned media from MCF-7 cells was determined by zymography was examined as described previously (AguirreGhiso et al., 1999) . The data presented are representative from experiments repeated at least two times Suppression of cell migration by PKCd D Jackson et al suppresses the ability to migrate and that the loss of PKCd increases cell motility. The data also show that the effect of PKCd on cell motility can be observed in normal rodent fibroblasts as well as in human breast cancer cells.
In this report, we have provided evidence that PKCd suppresses the ability of cells to migrate in culture. The effect was observed in two human breast cancer cell lines and in MEFs. Suppression of PKCd in MCF-7 cells also led to increased secretion of a metalloprotease that has been implicated in cell migration and metastasis. PKCd has previously been implicated as a tumor suppressor gene that prevents cell cycle progression (Jackson and Foster, 2004) . These data provide evidence that the tumor suppressing properties of PKCd extend to the metastatic phenotype of cell migration.
While PKCd clearly suppressed cell migration in the cell lines used here, elevated PKCd expression was reported to correlate with increased metastatic potential of rat mammary tumor cell lines (Kiley et al., 1999a, b) . PKCd was also reported to be required for the migration of breast cancer cells where elevated expression of the EGF receptor had been induced (Kruger and Reddy, 2003) . These apparently conflicting data point out that, as with cell proliferation, PKCd may have either positive or negative effects depending on the cellular context. We previously proposed that PKCd functions as a stress response kinase that can provide backup support for both proliferative and nonproliferative crises (Jackson and Foster, 2004) . In this context it is not surprising that PKCd can both suppress and enhance metastatic Figure 1 . The data presented are representative from an experiment repeated two times. MEFs from wild type and PKCd knockout mice (Miyamoto et al., 2002) were prepared from 14-to 17-day-old embryos. Cells were broken up with 0.5% trypsin and put in culture dishes in DMEM with 10% fetal calf serum. Cells were then routinely split 1 : 5. Cells used in experiments were less than 10 passages (Hata et al., 1993; Ohno et al., 1994) or a pSRD empty vector control (MCF-7/vec) and PKCd expression was determined 48 h later as in Figure 1 . (b) At this time, the plates were scraped with a rubber policeman and the number of cells that migrated back into the 'wounded' (scraped) area was determined 24 h later. (c) MMP-9 activity was determined was examined as in Figure 2 . The data presented are representative from experiments repeated at least two times It was previously reported (Lu et al., 1997 (Lu et al., , 1998 Hornia et al., 1999) that downregulating PKCd could transform rat fibroblasts overexpressing a tyrosine kinase, a common genetic defect in human breast cancer (Biscardi et al., 1999) . Downregulating PKCd also was shown to prevent apoptosis in response to serum withdrawal in cells with overexpression of the tyrosine Src (Zhong et al., 2002) . Survival signaling has also been linked with increased cell motility and invasion (Di Cristofano and Pandolfi, 2000) . The data provided here further link survival signals with increased cell motility and invasiveness. It is possible that the ability to prevent apoptosis may be linked to mechanisms that stimulate migration away from stressful conditions. This would provide a strong logic for the linking of these two activities. It may also provide evidence that the genetic changes that lead to metastasis are the same genes that are necessary to suppress default apoptotic programs that need to occur early in tumorigenesis.
A role for PKCd in human cancer has not been established; however it is of interest that the human PKCd gene is located on chromosome 3p in a region where there is considerable loss of heterozygosity (LOH) in a wide range of tumors (Yang et al., 2000) . This LOH has led to speculation that perhaps several tumor suppressor genes are present on chromosome 3p at the loci between 3p12 and 3p21 (Yang et al., 2000; Zabarovsky et al., 2002) . PKCd is located at 3p14 (Huppi et al., 1994) , thus it is not unreasonable that downregulation of PKCd could play an important role in cancer progression. To our knowledge, LOH has not been reported for chromosome 3p in the BT-549 cells; however, these cells have been reported to have a defect in the expression of the fragile histidine triad gene, which maps very close to the region of chromosome 3p where PKCd maps (Sevignani et al., 2003) . Thus, there may be a defect in this region of 3p in BT-549 cells that reduces gene expression that could be important for the malignant behavior of these cells.
The data present here suggest that elevating PKCd expression might be a target for suppressing tumor cell growth or inducing apoptosis in tumor cells. In this regard, bryostatin1, which targets PKCd, is in clinical trials for several tumor types (Clamp and Jayson, 2002; Marshall et al., 2002) . Most reports suggest that bryostatin1 is being used as an inhibitor of PKC isoforms; however above 100 nM, bryostatin1 both activates and prevents downregulation of PKCd (Szallasi et al., 1994a, b) and has been used to block the tumor-promoting effects of phorbol esters (Hennings et al., 1987; Lu et al., 1997) . Thus, it is plausible that the antiproliferative effects of bryostatin1 are due to the activation of a tumor suppressing effect of PKCd.
